Our Pipeline
At Apellis, we aim to transform treatment across a broad range of debilitating diseases driven by complement.
We brought forward the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved across four diseases. We are advancing that science in multiple clinical and pre-clinical programs in serious diseases with urgent unmet needs.
Ophthalmology
Product
Disease
Preclinical
Phase I
Phase II
Phase III
Approved
SYFOVRE®
(pegcetacoplan injection)
(pegcetacoplan injection)
GA
Approved
Marketed in the US
APL-3007 + SYFOVRE
GA
Phase I
Plan to initiate Ph2 in Q2 2025
RARE DISEASE
Product
Disease
Preclinical
Phase I
Phase II
Phase III
Approved
EMPAVELI®
(pegcetacoplan)*
(pegcetacoplan)*
PNH
Approved
Marketed in the US
C3G & Primary IC-MPGN
Approved
Marketed in the US
FSGS
Plan to initiate pivotal study in H2 2025
DGF
Plan to initiate pivotal study in H2 2025
Neurology
Product
Disease
Preclinical
Phase I
Phase II
Phase III
Approved
RNA therapies
Undisclosed
Preclinical
MULTIPLE THERAPEUTIC AREAS
Product
Disease
Preclinical
Phase I
Phase II
Phase III
Approved
Gene-edited FcRn therapy (Beam)
Undisclosed
Preclinical
Gene-edited complement therapies (Beam)
Undisclosed
Preclinical
Oral complement inhibitor
Undisclosed
Preclinical
*Sobi has global co-development and ex-U.S. commercialization rights for systemic pegcetacoplan
The safety and efficacy of the agents for the indications under investigation have not been established.